Compare UCAR & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UCAR | LYRA |
|---|---|---|
| Founded | 2013 | 2005 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0M | 5.6M |
| IPO Year | 2022 | 2020 |
| Metric | UCAR | LYRA |
|---|---|---|
| Price | $1.49 | $1.44 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | $5.00 | ★ $16.00 |
| AVG Volume (30 Days) | 39.9K | ★ 43.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,534,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.13 | $0.08 |
| 52 Week High | $4.98 | $37.50 |
| Indicator | UCAR | LYRA |
|---|---|---|
| Relative Strength Index (RSI) | 51.36 | 34.39 |
| Support Level | $1.44 | $1.21 |
| Resistance Level | $2.17 | $2.58 |
| Average True Range (ATR) | 0.12 | 0.15 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 79.89 | 25.29 |
U Power Ltd is involved in the provision of vehicle sourcing services. It is principally engaged in the provision of new energy vehicles development and sales; battery swapping stations manufacturing and sales; battery swapping services, and sourcing services. The company, as a broker, engaged in sales of vehicles between automobile wholesalers and buyers, including small and medium-sized vehicle dealers and individual customers located in lower-tier cities in China.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.